Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen for prevention of breast cancer in Japanese women with BRCA2 mutations
jRCTs031200222Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tamoxifen in breast cancer, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Incidence of breast cancer after 3 years of low-dose tamoxifen. Started Jan 2021; status: active, not recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCTs031200222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200222.